Evaluation of Antigen-specific T Cells in Patients With Antisynthetase Syndrome and Interstitial Lung Disease

Recruiting now

Conditions studied: Antisynthetase Syndrome

In brief

Antisynthetase syndrome (AS) is a rare overlapping myositis characterized by cellular and humoral autoimmune responses directed against aminoacyl-tRNA synthetases. Intesrtitial lung disease (ILD) is a leading cause of mortality in antisynthetase syndrome. Recently, antigen-specific IFN-γ+ CD4+ T cells have been identified in bronchoalveolar fluid (BAL) of patients with antisynthetase syndrome and ILD. Elevated levels of IL1β, IL12, IL18, TNFα, IL17A, IL22 have also been detected in peripheral blood of AS patients, especially those with progressive ILD. Implication of innate lymphoid cells (ILC) and mucosal-associated invariant T cells (MAIT) have not yet been studied in patients with AS. Targeted therapies against Th1 and Th17 cells may represent a promising treatment in patients AS patients with ILD. Investigators suppose that antigen-specific Th1 and Th17 cells, ILC and MAIT at ILD diagnosis are associated with ILD severity at diagnosis and could predict treatment response at 6 months. The main objective is to study the correlation between BAL antigen-specific Th1 and Th17 cells at ILD diagnosis and clinical evolution after 6 months of treatment according to initial ILD severity.

Key facts

Study ID

NCT05984394

Run by

Central Hospital, Nancy, France

People needed

24

Starts

2024-08-26

Expected to finish

2025-10-31

Last updated by the study team

2024-08-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient with new diagnosis of AS with ILD

You may not qualify if…

• Patient with ILD differential diagnosis
• Corticosteroid treatment, immunosuppresive or immunomodulatory drugs in the past 3 months before diagnosis

Where it is running

• Bernard Bonnotte — Dijon, France (enrolling)
• Julien Campagne — Metz, France (enrolling)
• Paul Decker — Nancy, France (enrolling)
• Loïs Bolko — Reims, France (enrolling)
• Alain Meyer — Strasbourg, France (enrolling)
• Olivier Benveniste — Paris, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.